A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years

Inclusion Criteria: * Postmenopausal osteoporosis * Patients who has a low bone mineral density at hip or vertebral * Patients who has an osteoporotic fracture at hip or vertebra Exclusion Criteria: * Hypersensitivity either to the active substance or to any of the excipients or to any biphosphonates. * Known metabolic bone disease excluding osteoporosis. * Serious systemic disorder treated with drugs interfering with bone metabolism. * Significant liver or renal failure * Pathologic fracture in the examined body area or elsewhere. * Previous anti-osteoporotic treatment within 12 months or less prior to the recruitment. * Patients with hypocalcaemia Other protocol-defined inclusion/exclusion criteria may apply